Prognostic Molecular Markers of Lu et al for a Patient with Stage I Non-Small Cell Lung Cancer (NSCLC)

Description

Lu et al evaluated a number of molecular markers in patients with Stage I non-small cell lung cancers (NSCLC). These can help to identify patients with a better or worse prognosis. The patients are from the University of Texas M.D. Anderson Cancer Center, Emory University and Institut Gustave Roussy (Villejuif, France).

Parameters:

(1) death-associated protein kinase II (DAPK) methylation

(2) IL-10 expression

Parameter	Finding	Points
DAPK methylation	absent	0
	present	1
IL-10 expression	absent	1
	present	0

prognostic score =

= SUM(points for the 2 parameters)

Interpretation:

• minimum prognostic score: 0

• maximum prognostic score: 2

• The higher the score worse the prognosis.

Prognostic Score	Risk Group	Disease Specific Survival at 10 Years
0 or 1	low risk	75%
2	high risk	0%

Additional prognostic factor:

(1) expression of cyclo-oxygenase 2 (COX-2, p value 0.08)

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10